No previous suggestions found.
1
Home
Companies

Harmony Biosciences

#4330

Rank

$1.96B

Marketcap

US United States

Country

Harmony Biosciences
Leadership team

Mr. Jeffrey S. Aronin (Founder & Non-Exec. Chairman)

Mr. John Charles Jacobs M.B.A. (Pres, CEO & Director)

Mr. Sandip S. Kapadia CPA, M.B.A. (Exec. VP & CFO)

Products/ Services
Biopharma, Biotechnology, Health Care
Number of Employees
100 - 500
Headquarters
Plymouth Meeting, Pennsylvania, United States
Established
2017
Company Registration
SEC CIK number: 0001802665
Net Income
20M - 100M
Revenue
100M - 500M
Traded as
HRMY
Social Media
URL
https://www.harmonybiosciences.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
History

Harmony was founded in 2015 by industry veterans, who share a common vision of discovering, developing and delivering novel treatments to those living with CNS disorders. The company’s first product, WAKIX® (pitolisant), was approved by the U.S. Food and Drug Administration (FDA) in June 2019 for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adult patients with narcolepsy. Harmonys pipeline includes multiple product candidates in various stages of clinical development for the treatment of various CNS disorders.

Mission
Harmony’s mission is to provide accessible, effective and safe therapies to improve the health and quality of life for patients living with CNS disorders.
Vision
Harmony’s vision is to be a CNS leader in innovation and excellence, proving value to patients, partners and shareholders.
Key Team

Dr. Jeffrey M. Dayno M.D. (Exec. VP & Chief Medical Officer)

Mr. Jeffrey Dierks M.B.A. (Exec. VP & Chief Commercial Officer)

Mr. Andrew Serafin J.D., M.B.A. (Exec. VP & Chief Strategy Officer)

Mr. David Bradshaw (Head of Technical Operations)

Ms. Sharon Goldbach (Head of Facilities Operations & Exec. Admin.)

Luis Sanay (Head of Investor Relations)

Mr. Christian Ulrich (Gen. Counsel)

Recognition and Awards
Harmony Biosciences has been awarded a contract from the US National Institutes of Health to develop treatments for pediatric neurological diseases such as neurofibromatosis and tuberous sclerosis.
References

https://in.investing.com/equities/harmony-biosciences-holdings

https://finance.yahoo.com/quote/HRMY/profile?p=HRMY

https://www.crunchbase.com/organization/harmony-biosciences

https://sec.report/CIK/0001802665

https://companiesmarketcap.com/

https://www.harmonybiosciences.com

Harmony Biosciences
Leadership team

Mr. Jeffrey S. Aronin (Founder & Non-Exec. Chairman)

Mr. John Charles Jacobs M.B.A. (Pres, CEO & Director)

Mr. Sandip S. Kapadia CPA, M.B.A. (Exec. VP & CFO)

Products/ Services
Biopharma, Biotechnology, Health Care
Number of Employees
100 - 500
Headquarters
Plymouth Meeting, Pennsylvania, United States
Established
2017
Company Registration
SEC CIK number: 0001802665
Net Income
20M - 100M
Revenue
100M - 500M
Traded as
HRMY
Social Media
URL
https://www.harmonybiosciences.com
About

Businessabc provides digital business directory, digital blockchain AI certification, resources, and marketplace for businesses, organisations, and professionals.

Contacts

businessabc@ztudium.com

Follow Us
Produced by
In collaboration with
Logo

Copyright 2024 © Businessabc powered by ztudium

Privacy Policy